Form 4: Pfizer Executive Lidia Fonseca Modifies Stock Appreciation Rights

Executive Vice President Lidia Fonseca modifies stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years.

Summary

• Lidia Fonseca, an Executive Vice President at Pfizer Inc., has modified her stock appreciation rights (TSRUs).
• The modification extends the vesting and settlement dates of certain outstanding TSRUs by two years.
• This action was taken pursuant to a one-time offer by Pfizer to modify Eligible TSRUs.
• The grant price and the number of shares underlying the Modified TSRUs remain unchanged.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a transaction related to executive compensation. It doesn't indicate positive or negative performance, just an administrative action.

Future Outlook

The document does not contain specific forward-looking statements beyond the modification of the TSRUs.

Industry Context

This filing reflects a common practice of companies using stock appreciation rights as part of executive compensation packages to align management's interests with those of shareholders. The modification offer suggests a strategic decision by Pfizer regarding its long-term incentive plans.

Comparison to Industry Standards

• Stock appreciation rights are a common component of executive compensation packages in the pharmaceutical industry, used by companies like Johnson & Johnson, Merck, and AbbVie.
• The specific terms and conditions of these rights, such as vesting schedules and modification options, can vary significantly between companies.
• Pfizer's modification offer is not necessarily standard but reflects a specific decision related to their compensation strategy.

Stakeholder Impact

• The modification of TSRUs could potentially impact the long-term incentives for the executive, aligning her interests with the long-term performance of the company, which could benefit shareholders.

Key Dates